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Abstract
Background: The monitoring of BCR-ABL transcript levels by real-time quantitative polymerase chain reaction
(RT-qPCR) has become important to assess minimal residual disease (MRD) and standard of care in the treatment
of chronic myeloid leukemia (CML). In this study, we performed a prospective, sequential analysis using RT-qPCR
monitoring of BCR-ABL gene rearrangements in blood samples from 91 CML patients in chronic phase (CP) who
achieved complete cytogenetic remission (CCyR) and major molecular remission (MMR) throughout imatinib
treatment.
Methods: The absolute level of BCR-ABL transcript from peripheral blood was serially measured every 4 to 12
weeks by RT-qPCR. Only level variations > 0.5%, according to the international scale, was considered positive.
Sequential cytogenetic analysis was also performed in bone marrow samples from all patients using standard
protocols.
Results: Based on sequential analysis of BCR-ABL transcripts, the 91 patients were divided into three categories:
(A) 57 (62.6%) had no variation on sequential analysis; (B) 30 (32.9%) had a single positive variation result obtained
in a single sample; and (C) 4 (4.39%) had variations of BCR-ABL transcripts in at least two consecutive samples. Of
the 34 patients who had elevated levels of transcripts (group B and C), 19 (55.8%) had a < 1% of BCR-ABL/BCR
ratio, 13 (38.2%) patients had a 1% to 10% increase and 2 patients had a >10% increase of RT-qPCR. The last two
patients had lost a CCyR, and none of them showed mutations in the ABL gene. Transient cytogenetic alterations
in Ph-negative cells were observed in five (5.5%) patients, and none of whom lost CCyR.
Conclusions: Despite an increase levels of BCR-ABL/BCR ratio variations by RT-qPCR, the majority of CML patients
with MMR remained in CCyR. Thus, such single variations should neither be considered predictive of subsequent
failure and nor an indication for altering imatinib dose or switching to second generation therapy. Changing of
imatinib on the basis of BCR-ABL/BCR% sustained increase and mutational studies is a prudent approach for
preserving other therapeutic options in imatinib-resistant patients.
Background
CML is a myeloproliferative disorder of blood stem cells
[1]. The causative molecular defect is the BCR-ABL pro-
tein, which is encoded by the Philadelphia chromosome
(Ph) [2]. This genetic anomaly arises from an exchange
of genetic material between chromosomes 9 and 22,
which results in the fusion of the breakpoint cluster
region (BCR) and the Abelson leukemia virus (ABL)
protooncogene [3,4]. The resulting gene encodes a con-
stitutively active protein kinase that activates a number
of proteins involved in cell-cycle regulation that hasten
cell division and affect DNA repair [5-8]. The clinical
course in CML is divided into a chronic phase (CP),
accelerated phase (AP), and blast phase (BP) [2]. During
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CP, there is a gross expansion of the myeloid compart-
ment, but the cells still retain the capacity to differenti-
ate and function normally. During AP, the myeloid
compartment undergoes transformation, with an
increased number of immature myeloid cells within the
bone marrow [2,9]. The terminal phase is transforma-
tion to acute leukemia [2,9]. The search for a specific
inhibitor of the BCR-ABL tyrosine kinase have resulted
in the identification of the specific inhibitor imatinib
mesylate (STI571), which has now become the standard
first-line therapy in patients with CP-CML [10,11]. Ima-
tinib, also known as Gleevec® (Novartis, Basel, Switzer-
land), is a selective inhibitor not only of ABL but also
for Kit and PDGFR kinases and exerts significant antil-
eukemic activity in the majority of CML patients. The
efficacy of imatinib was defined by quantifying BCR-
ABL transcripts to evaluate the residual disease burden
in patients who attained a complete cytogenetic
response (0% Ph positive chromosome in 20 meta-
phases) [12]. A > 3 log reduction in BCR-ABL fusion
transcript levels (1000 fold reduction; 0.1% BCR-ABL/
BCR ratio according to the international scale (IS)) from
the baseline mean, defined as a MMR, is a favorable
prognostic factor for the disease at any time during
therapy. In term of treatment responses, it has been
reported that this BCR-ABL kinase inhibitor produces a
complete hematological response in 98% of patients,
whereas CCyR occurs by 60-months follow-up in 87% of
newly diagnosed patients with CML in CP, and between
40% and 60% in late CP [13-19]. According to the most
recent results of the International Randomized Study of
Interferon versus STI571 (IRIS) trial, the estimated over-
all survival for patients still on imatinib was 85% at
8 years, or 93% when only CML-related deaths or
deaths prior to stem cell transplant were included.
A total of 92% were free of disease progression. The risk
of progressing to AP- or BP-CML was 0.9% in year 4 of
treatment, 0.5% in year 5, 0% in years 6 and 7, and 0.4%
in year 8. Among those who achieved CCyR, only 3%
progressed during the 8-year follow-up [20]. Moreover,
patients achieving MMR do even better, as no patient
who achieved MMR at 18 months had progressed at 5
years [12,16]. Patients who did not obtain a complete
hematologic response at 3 months or CCyR at 18
months were at increased risk of relapse [14,16]. Despite
this breakthrough in the treatment of CML patients, up
to 27% of the patients who achieved CCyR have been
shown to subsequently lose their response and conse-
quently fail to derive adequate or lasting clinical benefit
because of intolerance and/or resistance [21-24]. The
results published by Druker and co-workers demon-
strated that patients who had CCyR or in whom leuke-
mic burden of BCR-ABL had fallen by three orders of
magnitude (3 logs) or more had a significantly lower
risk of relapse than did patients without a CCyR [16].
A rise in BCR-ABL transcript levels detected during
imatinib therapy for Ph positive CML patients who
achieved CCyR is an alarming indicator of suboptimal
response and should trigger a subsequent, more strin-
gent, RT-qPCR assessment [25]. Together, these results
have prompted researchers to investigate whether it is
possible to distinguish CCyR patients at imminent risk
of relapse from those likely to derive benefit from imati-
nib treatment. As a consequence, identification of those
candidates with eventual molecular relapse early on
would be useful to change the monitoring frequency
and enable the use of alternative, more potent, second-
generation TKI therapies that may be more effective.
Molecular monitoring of the BCR-ABL transcript by
RT-qPCR in patients with CCyR during treatment is
arguably the single most important tool to evaluate the
outcome and to assess the risk of impending relapse.
Currently, a threshold of 5-fold to 10-fold (0.5 or 1 log)
increase in BCR-ABL transcript has been proposed for
molecular relapse. Against this background, we aimed to
investigate whether serial monitoring of BCR-ABL by
RT-qPCR, but not cytogenetic analysis, to measure
minimal residual disease (MRD), performed throughout
imatinib treatment in CP-CML patients having achieved
CCyR and MMR, could be safely used to monitor
patients and predict the probability of relapse within a
clinically relevant time period and to guide therapy.
Methods
Patients
Between June 1998 and September 2008, 217 adult
patients aged 16 to 75 with CML in CP undergoing
treatment with imatinib 400 mg/day at our center were
enrolled in this study at the time of diagnosis. Of these,
91 (41.9%) had reached both CCyR and MMR and were
considered for inclusion in this study. Imatinib was
introduced in our institution at the end of 2000; since
then, patients with CML have been treated with this
inhibitor every time the therapy-related toxicity allowed
it. The CP was defined by the presence of < 15% blasts,
< 20% basophils and < 30% blasts plus promyelocytes in
both peripheral blood and bone marrow; a platelet
count of at least 1 × 105 per cubic millimeter; and no
evidence of extra medulary disease [15,26,27]. The med-
ian age of the patients at diagnosis was 45 years (range
16 to 75 years). Of the 91 subjects, 29 (31.9%) had been
treated previously with interferon (IFN-a), and only 2 of
them had achieved CCyR. In these two patients, the
treatment was switched to imatinib due to IFN-a toxi-
city. The study cohort comprised 44 males and
47 females (Table 1). Tests of bone marrow morphology
and cytogenetic studies were carried out at diagnosis,
every 6 months until CCyR was achieved and then
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annually thereafter. Criteria for CCyR included morpho-
logically normal bone marrow with complete disappear-
ance of Ph-positive in at least 20 metaphases examined.
Cytogenetic relapse was defined by the detection of one
or more Ph-positive marrow metaphases and confirmed
by a subsequent cytogenetic study. CCyR was considered
durable if it lasted for at least 6 months. Patients were
reported to have achieved MMR or CMR if their BCR-
ABL/BCR ratios showed a reduction to 0.1% (≤ 3log) or
0.005% (≤ 4.5log), respectively, from a standardized
baseline according to the IS [28] and confirmed in two
subsequent samples. Numbers of BCR-ABL transcript
were measured by RT-qPCR at 4 to 12 weeks beginning
in February 2006. Variation levels of BCR-ABL were
considered positive if samples showed an increase of
more than 0.5% of transcripts, according to the IS, com-
pared to that seen in early MMR. The cutoff of 0.5%
was chosen with reference to the study by Mauro et al
[29]. All patients initially received imatinib at an oral
dose of 400 mg/day without concomitant chemotherapy.
Cytogenetic investigation
Cytogenetic analysis of bone marrow was routinely per-
formed using the Giemsa-Trypsin-Wright (GTW) stain
banding technique [30]. At least 20 metaphases were
analyzed for each sample.
Samples and RNA isolation
A volume of 10 to 30 ml of fresh peripheral blood from
each patient was collected in EDTA and treated with
0.144 M NH4Cl and, 0.01 M NH4HCO3 within 2 h of
collection to lyse the red cells, as previously described
[31]. Total leukocyte RNA was extracted by using RNA-
zol™(Invitrogen Life Technologies, San Diego, CA, USA)
according to the manufacturer’s instructions. cDNA was
synthesized from 2 μg RNA using random hexamers as
previously described [31].
Measurement of BCR-ABL transcript numbers and
mutational analysis
BCR-ABL and BCR transcripts in cDNA were measured
by RT-qPCR using the procedure described by Branford
et al. [32]. To minimize sampling error, the measure-
ments of BCR-ABL and BCR transcripts were performed
in duplicate. The copy numbers were calculated by
comparison with the standard curve generated from
serial dilutions of linearized plasmid containing the
BCR-ABL and BCR inserts as described previously [32].
BCR-ABL mutation analysis was performed as described
elsewhere [33].
Statistical analysis
Comparisons of the BCR-ABL/BCR ratios at various
time points during treatment and CCyR were performed
by the nonparametric Kruskal-Wallis test. All analyses
were performed using the SPSS software package (SPSS
Inc., Chicago, IL, USA).
Results
Of the 217 patients with CP-CML enrolled in this study,
91 (41.9%) had achieved CCyR and MMR after initiation
of imatinib therapy and were included in the prospective
monitoring study of MRD. Of these patients, CMR was
achieved in 39 patients (42.8%). The median time from
achievement of CCyR, MMR, and CMR to last follow-
up evaluation (March 2010) was 57 months (range 24 to
95), 36 months (range 19 to 46), and 22 months (range
6 to 49), respectively (Table 1). The median time from
starting treatment to achievement of CCyR, MMR, and
CMR was 7 months (range 6 to 50), 18 months (range 9
to 65), and 33 months (range 5 to 78), respectively. Two
patients already had CCyR with previous IFN-a treat-
ment but were switched to imatinib because of intoler-
ance of side-effects. Of the other 89 patients, 27 were
initially assigned to IFN-a but had crossed over to ima-
tinib due to an adverse event or because they did not
achieve CCyR by the designated target dates. Overall,
treatment with standard-dose imatinib produced an
optimal response in 73 (80.2%) patients. All but one of
these 73 patients never had a relapse, and their median
follow-up period was 53 months (range 37 to 141). Of
the other 18 (19.2%) patients, 10 (11%) had treatment
failure and 8 (8.8%) had suboptimal response according
to the definitions of failure of and suboptimal response
to imatinib proposed by the European Leukemia Net-
work [25]. None of these patients had genetic incidence
of mutations conferring resistance to imatinib. Of the
latter 18 patients, imatinib dose was escalated to
Table 1 Patient’s characteristics
Number of patients 91
Median age, years (range) 45 (16-75)
Male 44 (48.4)
Female 47 (51.6)
Prior therapy with interferon-a 29
Cytogenetic abnormalities in Ph-negative cells, no. (%) 5 (5.5%)
Time from initiation of imatinib to CCyR (months)
Median (range)
7
(6-50)
Time from initiation of imatinib to MMR (months)
Median (range)
18
(9-65)
Time from initiation of imatinib to CMR (months)
Median (range)
33
(5-78)
Time from achievement of CCyR to last evaluation (months)
Median (range)
57
(24-95)
Time from achievement of MMR to last evaluation (months)
Median (range)
36
(19-46)
Time from achievement of CMR to last evaluation (months)
Median (range)
22
(6-49)
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500 mg/day in 1 patient, to 600 mg/day in 14 patients
and up to 800 mg/day in the other 3 patients. Following
imatinib dose escalation, 12 patients did not achieve
CCyR at 18 months of treatment and remained under
the same treatment due to the unavailability of a second
inhibitor at that time; however, they did respond at later
times (up to 51 months). Five other patients had dose
reduction to 300 mg/day because of intolerance or side-
effects (four with neutropenia and one with congestive
heart failure) and, as of this writing, are still in MMR
(15 to 42 months). One patient who received further
imatinib dose escalation to 800 mg/day required dose
reduction to 400 mg/day because of higher hematologi-
cal toxicity.
Based on sequential analysis of BCR-ABL transcripts,
the 91 patients were divided into three subgroups. Sub-
group A consisted of patients who had no variation on
sequential analysis. Patients who had a single positive
variation result obtained in a single sample were allo-
cated to subgroup B. Subgroup C consisted of patients
who had variations of BCR-ABL transcripts in at least
two consecutive samples. As depicted in Table 2, 57
(62.6%) patients were assigned to group A, 30 (32.9%) to
group B and 4 (4.39%) to group C. Of the 34 patients
(group B and C) who had at least a single variation in
BCR-ABL RT-qPCR, 19 (55.8%) had a < 1% of BCR-
ABL/BCR ratio, 13 (38.2%) patients had a 1% to
10% increase and 2 patients had a >10% increase of
RT-qPCR.
Only 4 patients (group C) had variations of BCR-ABL
transcripts in consecutives samples. One of these four
patients developed the M244V mutation. Despite having
CCyR, the patient’s imatinib was discontinued and dasa-
tinib was started at a dose of 100 mg once daily and
regained MMR in the last evaluation (March 2010).
Another patient have to take more medications on a
daily basis for sickle cell anemia and admitted to having
missing some doses. During follow-up, the other two
patients who had a >10% increase of RT-qPCR lost
CCyR without evidence of mutation on the ABL kinase
domain. Of these two cases, one had not achieved CCyR
at 18 months while taking imatinib at 400 mg/day. The
same patient achieved both CCyR and MMR after
26 months with an increase of imatinib to 800 mg/day;
however, 4 months later the transcript levels had
increased to 11.54% compared to baseline. As a result,
treatment was switched to nilotinib 400 mg twice daily
and further to bosutinib 500 mg/day, but without
response. The possibility of non-compliance appeared
inevitable and was discussed repeatedly, and finally
admitted by the patient. The patient was on dasatinib
100 mg/day and had achieved CCyR after 4 months of
therapy. The second patient achieved both CCyR and
MMR after 6 and 18 months of therapy, respectively.
The same patient maintained MMR for only 4 months,
and molecular analysis of peripheral blood revealed a
continuous increase of the BCR-ABL transcript from
0.08% to 1.8% and then to 3.6%. However, the latter
patient had gastric intolerance of nausea and vomiting
despite the use of antiemetic, which may have impaired
drug absorption. As a consequence, imatinib was safely
switched to nilotinib 400 mg twice daily, and the patient
regained CCyR and MMR at 6 months.
As shown in table 2, CMR was achieved in 39 patients
(29 in group A, 10 in group B, none in group C) and of
them, only 9 patients (8 in group A and 1 in group B)
have ongoing CMR. There was no significant difference
between patients in group B in relation to CMR (P =
0.11). Of the other 30 patients who achieved CMR, 18
had BCR-ABL/BCR ratio increase from 0.005% to 0.01%,
7 had BCR-ABL/BCR ratio raised between 0.005% -
0.1%, and 5 had increased ratio greater than 0.5%. Of
note, these variations were observed in some of the col-
lected samples during follow-up period.
Previous exposure to IFN was documented in
29 patients, among whom 17 were in group A, 11 in
group B (7 with BCR-ABL transcripts variation < 1%,
and 4 with variations between 1-10%), and 1 in group C.
Table 2 Molecular, treatment with imatinib and cytogenetic assessment of clinical samples of CML patients studied
No. of Patients Group A (n 57) Group B (n 30) Group C (n 4)
Variations in BCR-ABL/BCR %
0.5-<1 19 0 19 0
1-10 13 0 11 2
>10 2 0 0 2
Imatinib dose during follw up until achievement of CCyR
No change 68 45 21 2
Dose escalation 18 9 7 2
Dose reduction 5 3 2 0
Loss of CCyR 2 0 0 2
Alteration in Ph negative cells 5 4 1 0
Achievement of CMR 39 29 10 0
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Among the 39 patients with CMR, 12 were pretreated
with IFN-a: eight in group A, and four in group B.
There was no difference in response rate to imatinib
between the group that were pre-treated with IFN-a, or
those that did not have IFN-a before.
Our follow-up cytogenetic evaluations revealed five
(5.5%) patients with chromosomal abnormalities in
Ph-negative cells (Table 2). Of these, three patients (two
in group A and one in group B) had developed trisomy
8, one patient had inv(9) (group A), and one had
monosomy 7 (Group A). These cytogenetic alterations
were transient in four patients (lasting 6 to 40 months),
and none of the five patients lost CCyR.
Discussion
Since the introduction of imatinib in 1998, there has
been a significant decline of 30% in treatment-related
mortality for patients exposed to therapy compared with
a historical control group of CML patients who under-
went stem cell transplantation prior to the availability of
imatinib [34]. Following the introduction of imatinib as
first-line therapy for patients with CML, CCyR has
become a more frequent event in these patients (> 85%),
and there has been a dramatic improvement of overall
survival (98%) and progression-free survival (99%) with
the achievement of CCyR after 18 months of treatment,
compared with 76% overall and 87% progression-free
survival, with partial cytogenetic response [16,35,36].
Several studies have reported that patients with both
CCyR and MMR have lower rates of CCyR loss. Some
reported higher event-free survival compared with those
who achieved CCyR but not MMR [16,37-39]. Several
researchers have found greater progression-free survival
in patients with MMR [23,32,40], but others have not
supported this observation [16,36,39]. The impact on
overall survival has not been confirmed [36,38], but the
change of treatment to a second-generation inhibitor
soon after the loss of CCyR may explain this lack of
relevance to overall survival.
In this report, we investigated the potential of RT-
qPCR measurement of BCR-ABL transcript levels to
predict cytogenetic relapse by monitoring the BCR-ABL
transcript every 4 to 12 weeks throughout imatinib
treatment in 91 CP-CML patients who had achieved
CCyR and MMR. At least one variation in RT-qPCR
and relapse developed at the molecular level were
detected in 34 (37.3%) patients and only 4 (group C)
had variations of BCR-ABL transcripts in consecutives
samples. The raise in BCR-ABL/BCR ratio was common
even in patients who had achieved CMR. The only two
patients who had a > 10% increase, were also the only
two who lost CCyR. Overall, these findings indicate that
a rising trend of BCR-ABL transcripts is more meaning-
ful than a single elevation. Of note, one of these patients
appeared to have become refractory not only to imatinib
but also to nilotinib and bosutinib. The patient was con-
fronted with the results of the laboratory follow-up and
then admitted therapy noncompliance. Thus, in addition
to technical variation, drug resistance and treatment fail-
ure during imatinib therapy, a rise in BCR-ABL tran-
script may indicate inadequate imatinib dose,
particularly a lack of patient compliance to the therapy
[41-43]. In our follow-up study by RT-qPCR, none of
the patients who achieved MMR for > 1 year had lost
CCyR. Unlike previous studies, the molecular monitor-
ing was performed in short time intervals between sam-
ple collections (every 4 to 12 weeks), so greater
variations in the number of transcripts were observed.
Apart from our study, the use of BCR-ABL RT-qPCR
to distinguish CCyR patients at imminent risk of relapse
from those likely to derive benefit from imatinib treat-
ment, has already been the subject of several studies
[22,23,25,37,38,44-47]. For instance, Marin et al. [37]
quantitated BCR-ABL expression by real-time PCR in
peripheral blood in 161 patients who had initiated imati-
nib therapy early after diagnosis of CML in CP and who
had achieved CCyR. The results of their study indicated
that increases in the transcript levels that do not reach
the MMR status have no prognostic value, while a two-
fold increase in the transcript levels that do amount to
MMR is a critical factor for predicting relapse. Palandri
et al. [48] measured BCR-ABL levels by real-time PCR
in peripheral blood in 130 patients with CML in CP
who achieved CCyR with imatinib therapy after IFN-a
failure, and they found that patients in unstable MMR,
defined by transcript levels sometimes above the MMR
(between 0.5 and 1log of the MMR), had a similar risk
of losing CCyR as those who had never achieved MMR.
The recent study by Kantarjian et al. [47] evaluated the
clinical relevance of increased of BCR-ABL detected in
at least two consecutive samples from 116 patients in
stable CCyR on imatinib therapy for longer than 18
months. Contrary to the results reported by Palandri
et al., Kantarjian et al found that most of the patients
with increases in BCR-ABL remain in CCyR and that
patients who had CML progression (9.5%) were those
who either lost MMR or never had MMR and who had
> 1 log increase of BCR-ABL transcript. Our results are
thus consistent with those of Kantarjian et al.
The emergence of cytogenetic abnormalities in Ph-
negative cells have been described to occur after the
selective suppression of the predominant Ph-positive
clones with imatinib in 10% of cases [49-53], but the
cause and clinical significance of this phenomenon has
not been fully clarified. The most frequent cytogenetic
abnormalities are -Y, +8, -7 or 7q-, the first being
reported as a common phenomenon in healthy men
with advanced age [51,54]. Several studies have reported
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that most patients with these clonal chromosomal
abnormalities do not evolve to myelodysplastic syn-
drome (MDS) or acute myeloid leukemia (AML) or pro-
gress to CML [38,49-51,55,56], and such cytogenetic
alterations are often transient [50,51]. However, a few
cases of evolution to MDS or AML have been reported
and have been correlated with possible damage to the
Ph-negative stem cell secondary to previous treatment
as a result of a long disease process [55-57]. Generally,
the presence of these cytogenetic abnormalities in Ph-
negative cells provides a warning signal, as described by
the European Leukemia Network [58]. In our study,
only five patients (5.5%) developed cytogenetic abnorm-
alities in Ph-negative cells, and none of them lost CCyR.
Only one of them was in late CP (group A, trisomy 8)
and had received IFN-a prior to initiation of imatinib,
while the others were in early CP and started imatinib
as a first-line therapy. One patient developed inv(9)
which is considered a structural chromosomal variation
[59]. It is possible that the emergence of clonal abnorm-
alities could be a consequence of a long disease process
or prior therapy negatively inhibiting normal hematopoi-
esis, thus providing the selective pressure for the out-
growth of a resistant Ph-negative clone. Alternatively, it
could be a result of direct effect of imatinib.
Overall, our data are consistent with the findings of
two recent studies [36,56] and lend further support to
the new recommendations of the European Leukemia
Network of performing cytogenetic evaluation either
1 year after obtaining CCyR or regularly if molecular
monitoring is not available [58].
Conclusions
In conclusion, fluctuation in BCR-ABL/BCR is a com-
mon event and most of them may be merely due to
inadequate adherence, variability in the sampling or
measurement procedure. Evidence from this work and
other published studies demonstrate that most patients
with CP-CML in MMR and CMR, even with variations
in PCR, remain in CCyR. Thus, such single variations
should neither be considered predictive of subsequent
failure and nor an indication for altering imatinib dose
or switching to second generation therapy. We would
like to emphasize that changing of imatinib on the basis
of sustained increase of BCR-ABL/BCR ratio and muta-
tional studies is a prudent approach for preserving other
TKIs therapeutic options in patients with imatinib
resistance.
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